Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA

Folia Biologica (Czech Republic)

Volumn 58, Issue 6, 2012, Pages 246-250

  Chmelařová, Marcela ^a   Krepinska E ^a   Spacek J ^a   Laco, J ^a   Nekvindova J ^a   Palicka V ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

CDH13; DNA methylation; Epigenetics; MS MLPA; Ovarian cancer

Indexed keywords

CDH13 PROTEIN; ESR1 PROTEIN; GATA5 PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TRANSCRIPTION FACTOR PAX5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR SUPPRESSOR 1 PROTEIN;

ARTICLE; CANCER GENETICS; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; METHYLATION; METHYLATION SPECIFIC MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVARY CANCER; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 84879817906     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Asadollahi, R., Hyde, C. A., Zhong, X. Y. (2010) Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol. Oncol. 118, 81-87.
2. Bol, G. M., Suijkerbuijk, K. P., Bart, J., Vooijs, M., van der Wall, E., van Diest, P. J. (2010) Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57, 363-370.
3. Bonazzi, V. F., Nancarrow, D. J., Stark, M. S., Moser, R. J., Boyle, G. M., Aoude, L. G., Schmidt, C., Hayward, N. K. (2011) Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One 6, e26121.
4. Chan, K. Y., Ozçelik, H., Cheung, A. N., Ngan, H. Y., Khoo, U. S. (2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 62, 4151-4156. (Pubitemid 34791087)
5. Chmelařová, M., Palička, V. (2011) The most frequent methods used for DNA methylation analysis. Cas. Lek. Cesk. 150, 442-445. (in Czech)
6. Feng, W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J. P., Fishman, D. M., Yu, Y., Bast Jr. R. C. (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489-1502. (Pubitemid 351441161)
7. Gras, E., Catasus, L., Argüelles, R., Moreno-Bueno, G., Palacios, J., Gamallo, C., Matias-Guiu, X., Prat, J. (2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92, 2829-2836. (Pubitemid 33091919)
8. Gaudet, M. M., Campan, M., Figueroa, J. D., Yang, X. R., Lissowska, J., Peplonska, B., Brinton, L. A., Rimm, D. L., Laird, P. W., Garcia-Closas, M., Sherman, M. E. (2009) DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiol. Biomarkers Prev. 18, 3036-3043.
9. Ibanez de Caceres, I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., Cairns, P. (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64, 6476-6481. (Pubitemid 39297903)
10. Jones, P. A., Baylin, S. B. (2007) The epigenomics of cancer. Cell 128, 683-692. (Pubitemid 46273572)
11. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Yamada, H., Yamamoto, R., Sakuragi, N., Enokida, H., Verma, M., Dahiya, R. (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104, 1924-1930. (Pubitemid 41513176)
12. Karlan B. Y. (2009) Patients at high risk for ovarian cancer should undergo routine screening. Clinical Ovarian Cancer 5, 83-89.
13. Mei, F. C., Young, T. W., Liu, J., Cheng, X. (2006) RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J. 20, 497-499. (Pubitemid 46671228)
14. Moelans, C. B., Verschuur-Maes, A. H., van Diest, P. J. (2011) Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J. Pathol. 225, 222-231.
15. Montavon, C., Gloss, B. S., Warton, K., Barton, C. A., Statham, A. L., Scurry, J. P., Tabor, B., Nguyen, T. V., Qu, W., Samimi, G., Hacker, N. F., Sutherland, R. L., Clark, S. J., O'Brien, P. M. (2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 124, 582-888
16. Nygren, A. O., Ameziane, N., Duarte, H. M., Vijzelaar, R. N., Waisfisz, Q., Hess, C. J., Schouten, J. P., Errami, A. (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 33, e128.
17. Palmisano, W. A., Crume, K. P., Grimes, M. J., Winters, S. A., Toyota, M., Esteller, M., Joste, N., Baylin, S. B., Belinsky, S. A. (2003) Aberrant promoter methylation of the transcription factor genes PAX5 α and β in human cancers. Cancer Res. 63, 4620-4625. (Pubitemid 36951039)
18. Roh, H. J., Suh, D. S., Choi, K. U., Yoo, H. J., Joo, W. D., Yoon, M. S. (2011) Inactivation of O6-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types. J. Obstet. Gynaecol. Res. 37, 851-860.
19. Tavassoli, F. A, Devilee, P. (eds.) (2003) World Health Organization. Classification of Tumors. Pathology and genetics: tumors of the breast and female genital organs. pp. 113-202. IARC Press, Lyon.
20. van Vlodrop, I. J., Niessen, H. E., Derks, S., Baldewijns, M. M., van Criekinge, W., Herman, J. G., van Engeland, M. (2011) Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17, 4225-4231.
21. Wakana, K., Akiyama, Y., Aso, T., Yuasa, Y. (2006) Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett. 241, 281-288. (Pubitemid 44163044)
22. Yoon, J. H., Dammann, R, Pfeifer, G. P. (2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94, 212-217. (Pubitemid 32911415)